, Volume 14, Issue 4, pp 375–380

Circulating testosterone and prostate cancer. A brief review

Open Access
Déficit Androgénique Prostate et Androgène Lié à l’Âge


In vitro andin vivo studies show that androgens stimulate prostate cancer. However, evidence from epidemiological studies of an association between circulating levels of androgens and prostate cancer risk has been inconsistent, but most studies have likely been undersized given that the association may be relatively weak.

We review prospective studies on the association of serum levels of free and total testosterone, the principal androgen in circulation with risk of prostate cancer.

No significant association between total or free testosterone and risk of prostate cancer was found in studies that together included 1,525 cases of prostate cancer and 4,349 controls.

No support was found for the hypothesis that high levels of circulating testosterone within a physiological range stimulate development and growth of prostate cancer. Intraprostatic androgen metabolism may still be of importance for prostate cancer development.

Key words

prostate cancer androgens testosterone epidemiology prospective studies 


  1. 1.
    ANDERSON D.C., THORNER M.O., FISHER R.A. et al.: Effects of hormonal treatment on plasma unbound androgen levels in hirsute women. Acta Endocrinol. Suppl. (Copenh), 1975, 199: 224.Google Scholar
  2. 2.
    BIANCHINI F., KAAKS R., VAINIO H.: Overweight, obesity, and cancer risk. Lancet Oncol., 2002, 3: 565–574.PubMedCrossRefGoogle Scholar
  3. 3.
    BLADOU F., VESSELA R.L., BUHLER K.R. et al.: Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int. J. Cancer, 1996, 67: 785–790.PubMedCrossRefGoogle Scholar
  4. 4.
    BOSLAND M.C.: The role of steroid hormones in prostate carcinogenesis. Journal of the National Cancer Institute Monographs, 2000, 27: 67–73.Google Scholar
  5. 5.
    CALLE E.E., RODRIGUEZ C., WALKER-THURMOND K. et al.: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 2003, 348: 1625–1638.Google Scholar
  6. 6.
    DORGAN J.F., ALBANES D., VIRTAMO J. et al.: Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol. Biomarkers Prev., 1998, 7: 1069–1074.Google Scholar
  7. 7.
    EATON N.E., REEVES G.K., APPLEBY P.N. et al.: Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br. J. Cancer, 1999, 80: 930–934.PubMedCrossRefGoogle Scholar
  8. 8.
    GANN P.H., HENNEKENS C.H., MA J. et al.: Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer. Inst., 1996, 88: 1118–1126.PubMedCrossRefGoogle Scholar
  9. 9.
    GAPSTUR S.M., GANN P.H., KOPP P. et al.: Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol. Biomarkers Prev., 2002, 11: 1041–1047.PubMedGoogle Scholar
  10. 10.
    GIOVANNUCCI E., STAMPFER M.J., KRITHIVAS K. et al.: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA, 1997, 94: 3320–3323.PubMedCrossRefGoogle Scholar
  11. 11.
    GRUENEWALD D.A., MATSUMOTO A.M.: Testosterone supplementation therapy for older men: potential benefits and risks. J. Am. Geriatr. Soc., 2003, 51: 101–115.PubMedCrossRefGoogle Scholar
  12. 12.
    GUESS H.A., FRIEDMAN G.D., SADLER M.C. et al.: 5 alphareductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol. Biomarkers Prev., 1997, 6: 21–24.PubMedGoogle Scholar
  13. 13.
    HEIKKILA R., AHO K., HELIOVAARA M. et al.: Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer, 1999, 86: 312–315.PubMedCrossRefGoogle Scholar
  14. 14.
    HSING A.W., COMSTOCK G.W.: Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol. Biomarkers Prev., 1993, 2: 27–32.PubMedGoogle Scholar
  15. 15.
    HSING A.W., REICHARDT J.K., STANCZYK F.Z.: Hormones and prostate cancer: current perspectives and future directions. Prostate, 2002, 52: 213–235.PubMedCrossRefGoogle Scholar
  16. 16.
    IRANI J., RAVERY V., PARIENTE J.L. et al.: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J. Urol., 2002, 168: 1985–1988.PubMedCrossRefGoogle Scholar
  17. 17.
    KAAKS R., LUKANOVA A., SOMMERSBERG B.: Plasma androgens, IGF-I, body size and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic. Dis., 2000, 3: 157–172.PubMedCrossRefGoogle Scholar
  18. 18.
    KYPRIANOU N., ENGLISH H.F., ISAACS J.T.: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res. 1990, 50: 3748–3753.PubMedGoogle Scholar
  19. 19.
    LUCIA M.S., BOSTWICK D.G., BOSLAND M. et al.: Workgroup I: rodent models of prostate cancer. Prostate, 1998, 36: 49–55.PubMedCrossRefGoogle Scholar
  20. 20.
    MAKRIDAKIS N.M., REICHARDT J.K.: Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol. Rev., 2001, 23: 24–29.PubMedGoogle Scholar
  21. 21.
    MONTGOMERY J.S., PRICE D.K., FIGG W.D.: The androgen receptor gene and its influence on the development and progression of prostate cancer. J. Pathol., 2001, 195: 138–146.PubMedCrossRefGoogle Scholar
  22. 22.
    MORALES A.: Androgen replacement therapy and prostate safety. Eur. Urol., 2002, 41: 113–120.PubMedCrossRefGoogle Scholar
  23. 23.
    MORLEY J.E., PATRICK P., PERRY H.M..3.: Evaluation of assays available to measure free testosterone. Metabolism, 2002, 51: 554–559.PubMedCrossRefGoogle Scholar
  24. 24.
    NAIR B., WILT.T., MACDONALD R. et al.: Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. The Cochrane database of systematic reviews, 2002, Computer File 1: CD003506.Google Scholar
  25. 25.
    NOMURA A.M., STEMMERMANN G.N., CHYOU P.H. et al.: Serum androgens and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 1996, 5: 621–625.Google Scholar
  26. 26.
    NORMAN R.W., COAKES K.E., WRIGHT A.S. et al.: Androgen metabolism in men receiving finasteride before prostatectomy. J. Urol., 1993, 150: 1736–1739.PubMedGoogle Scholar
  27. 27.
    STATTIN P., LUMME S., TENKANEN L. et al.: High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study. Int. J. Cancer, 2004, 108: 418–424.PubMedCrossRefGoogle Scholar
  28. 28.
    SINNECKER G.: Stability of sex-hormone-binding globulin in serum and plasma. Clin. Chem., 1989, 35: 1253–1254.PubMedGoogle Scholar
  29. 29.
    THOMPSON I.M., GOODMAN P.J., TANGEN C.M. et al.: The influence of finasteride on the development of prostate cancer. N. Engl. J. Med., 2003, 349: 215–224.PubMedCrossRefGoogle Scholar
  30. 30.
    UKKOLA O., GAGNON J., RANKINEN T. et al.: Age, body mass index, race and other determinants of steroid hormone variability: the HERITAGE Family Study. Eur. J. Endocrinol., 2001, 145: 1–9.PubMedCrossRefGoogle Scholar
  31. 31.
    VATTEN L.J., URSIN G., ROSS R.K. et al.: Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol. Biomarkers Prev., 1997, 6: 967–969.PubMedGoogle Scholar
  32. 32.
    VERMEULEN A.: Androgen replacement therapy in the aging male-a critical evaluation. J. Clin. Endocrinol. Metab., 2001, 86: 2380–2390.PubMedCrossRefGoogle Scholar
  33. 33.
    VERMUELEN A., VERDONCK G.: Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J. Clin. Endocrinol. Metab., 1992, 74: 939–942.CrossRefGoogle Scholar
  34. 34.
    VERMEULEN A., VERDONCK L., KAUFMAN J.M.: A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab., 1999, 84: 3666–3672.PubMedCrossRefGoogle Scholar
  35. 35.
    WEBBER M.M., BELLO D., QUADER S.: Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines. Prostate, 1996, 29: 386–394.PubMedCrossRefGoogle Scholar

Copyright information

© Société d’Andrologie de Langue Française 2004

Authors and Affiliations

  1. 1.Dept of Urology and AndrologyUmeå University HospitalUmeåSweden

Personalised recommendations